Home > Rheumatology > ACR 2022 > ACR 2022 Congress Round-Up > Stimulation of PD-1: a new concept to treat RA

Stimulation of PD-1: a new concept to treat RA

Presented By
Prof. Paul Emery, University of Leeds, UK
ACR 2022
Phase 2
Peresolimab was significantly superior to placebo in reducing the Disease Activity Score-28 with C-reactive protein (DAS28-CRP) as well as Clinical Disease Activity Index (CDAI) in patients with rheumatoid arthritis (RA). The safety profile did not demonstrate a dose effect of the study drug. The programmed cell death protein 1 (PD-1) agonist peresolimab represents a novel mode of action for the therapy of RA. “We hypothesised that peresolimab binding to PD-1, which is a checkpoint inhibitory receptor, could stimulate physiological immune pathways and restore immune homeostasis,” Prof. Paul Emery (University of Leeds, UK) informed [1]. The presented phase 2a trial (NCT04634253) enrolled participants with moderate-to-severe active RA who had a prior failure to not more than 2 conventional synthetic, biologic, or targeted synthetic DMARDs. In this study, 98 pa...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on